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Nature of the cluster and its evolution during the last 10 years  
The life science cluster Medicon Valley are located in the bi-national Øresund region which 
spans greater Copenhagen in Denmark and Scania in southern Sweden, including the university 
town Lund and Sweden’s third biggest city, Malmö (see figure 1). In 2000, these two national 
parts were physically connected by the establishment of the 18 kilometer long Øresund fixed link 
(bridge and tunnel).  
 
Figure 1. Map of Medicon Valley 
Copenhagen 
Lund 
Malmö 
 
 
 
In a recent study of the globalization of biotechnology and life science industry, Phil Cooke 
(2005) identifies a hierarchy of globally networked bioregions in terms of size and level of 
innovation activities. A handful of US ‘megacenters’ like Boston, New York and San Francisco 
are in the top of this chart, followed by European centres like Munich, Cambridge, Stockholm-
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Uppsala and Oxford. Medicon Valley can be considered a potential megacentre if seen as one bi-
national cluster (see table 1).  
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4      2,650    $250.0 m.        $105 million (2000) 
Oxford        46      3,250    $120.0 m.        $70 million (2000) 
 
es of new 
drug candidates require substantial cash-flow. Another important factor is the need for close 
relat
characteristics, has created new requirements for successful bioregions. The regions need to host a 
Table 1. Comparative Global Performance Indicators for bioregions 
 
Location    DBFs  Life Scientists  VC          Big Pharma Funding 
 
Boston     141      4,980    $601.5 m.        $800m./annum 96-0
San Francisco    152      3,090    $1,063.5 m.     $400m./annum 96-01
New York    127      4,790    $1,730 m.        $151.6m. (2000) 
Munich      120      8,000    $400.0 m.       $54 million (2001) 
Medicon Valley   104       5,950    $ 80.0 m.         $300 million (2002
San Dieg        94     1,430    $432.8 m.        $320
Stockholm-U p a   87      2,998    $90.0 m.          $250
Washingt n C     83      6,670    $49.5 m.          $360
Toronto         73      1,149    $120.0 m.       NA 
Montrea        72       822     $60.0 m.          NA 
Zurich        70      1,236    $57.0 m.          NA 
Cambridge       5
Source: Cooke, 2005 
Since the 1970s the life science sector has been led and dominated by large pharmaceutical 
companies (big pharma), producing and commercializing relatively few biotechnology based 
drugs. In the past decade the number of possible applications of biotechnology has multiplied, and 
big pharma is therefore increasingly dependent on new knowledge created by dedicated 
biotechnology firms (DBFs). In turn, DBFs are heavily dependent on the financial resources of 
big pharma (and venture capital) since the large up-front costs and long development tim
ions with universities, research hospitals and other research organisations for intellectual 
property and knowledge inputs as well as the recruitment of skilled research personnel.  
This ‘transformation’ of biotech, with increased variety and complexity as major 
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critical mass of strong actors representing not only the pharmaceutical industry but the whole 
value chain, provide suitable opportunities for basic research as well as commercialization, and 
link up with knowledge sources in other bioregions across the globe. This paper describes the 
development of the Medicon Valley biotech cluster the last decade, both assessing how the cluster 
equirements and identifying future challenges that the cluster faces. 
Evolution of the cluster 
spin-offs (e.g. Camurus, Cellavision, Genovis and Wieslab) while others are local sub-
units of global biotech companies (e.g. Acadia with headquarter in San Diego and research unit in 
Malm
y 
research spin-off from Neurosearch), have contributed to a renewal of the bioregion meeting new 
requirem
has adapted to these new r
The life science sector in Scania has long traditions through the presence of Astra 
(subsequently merged with Zeneca to become AstraZeneca) and Pharmacia (subsequently merged 
with Upjohn to become Pharmacia & Upjohn, and eventually acquired by Pfizer). Both these 
companies historically located significant research activities in Lund; AstraZeneca are still present 
with a major research unit employing 1 200 persons. After the Pharmacia merger the research on 
cancer and immunology was spun out to form the Lund based Active Biotech AB in 1997, while 
the rest of the company’s activities disappeared from the region (the company still has a unit in 
Uppsala). Active Biotech AB is today, with 90 employees, the second largest and second oldest 
DBF in the region, after BioInvent International AB which today employs a staff of around 100 
persons. BioInvent was created in 1995 by researchers at Lund University that wanted to 
commercialize their research. Besides these two medium-sized firms, the Swedish part of the 
region hosts about 35 other DBFs of varying size and age. A large share of the companies are 
university 
ö).  
Also the Danish part of the region has been a strong milieu for life science for a long time. 
Large anchor firms like Novo Nordisk and Lundbeck are still among the major players in the 
world, but local spin-off companies like Novozymes (research part of Novo Nordisk), local but 
world leading diagnostics companies like Dako (founded in Copenhagen 1966, today with sub-
units in Colorado and California), and strongly associated pairs of complementary companies like 
Neurosearch (a biopharmaceuticals spin-off from Novo Nordisk) and NsGene (cell technolog
ents on the global market. In total the Danish part of the region hosts about 100 DBFs.  
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The term Medicon Valley was first introduced in 1994 by the Øresund Comittee. This is a 
forum of public agencies from the Danish and Swedish part of the region with the mission to 
stimulate binational regional development. Feeding into the existing industrial specialization of 
the region, it decided to focus specifically on the emerging field of biotechnology. Besides the 
historical localization of big pharma (in fact, 60% of Scandinavian pharmaceutical companies are 
located in Medicon Valley) an enormous potential for life sciences within the region was 
identified as it hosts 11 universities and 26 hospitals. However, the potential of becoming a global 
bioregion or ‘megacentre’ are conditioned by the ability to achieve integration between the two 
nationa
hich approximately 70% are located on the Danish side of 
Medicon Valley. Also university research, representing the earliest stages of the biotech value 
chain, has increased
l counterparts. This was hence the main ambition with the creation of Medicon Valley. 
The efforts to promote actual integration, making it justified to speak about Medicon Valley 
as one cross-border cluster (as opposed to two separate national clusters with less dignity on the 
global biomarket), took off for real with the formation of Medicon Valley Academy (MVA) in 
1995 (in 1997, the organization changed its name to Medicon Valley Alliance). MVA was 
initiated by Lund and Copenhagen Universities as an EU Interreg II project. The rationale behind 
the initiative was to stimulate the formation of a cross-border life science region by promoting 
local integration and cross-fertilization between industry and academia. The MVA initiative has 
contributed to the development of the cluster, not the least because of its power of attraction on 
venture capital, research funds and human capital. This, together with the general transformation 
of biotechnology towards increased variety and complexity, has led to a shift in dominance from 
large pharmaceutical companies taking care of the entire value chain to small DBFs mainly 
focusing on basic research and early stages of development. Several of the large pharmaceutical 
companies have gradually downsized their production activities in the region, yet increasing their 
research facilities. At the same time there has been an impressive growth in number of DBFs. 65 
new DBFs have been established since 1998, and if medical technology companies and R&D 
based service firms are included, the number of start-ups exceeds 100. Only in the period 2004-
2005 29 new small R&D based firms were established in the region (MVA, 2006). Today there 
are approximately 130 DBFs of w
 in the region.  
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This shift in dominance from single actors spanning the entire value chain to actors mainly 
representing the early stages has also affected the integration of the cluster and the needs for 
linking up with other bioregions. Actors in life science are today by necessity part of global 
research communities rather than regional ones. Due to their extreme specialization they are 
forced to seek collaboration among the few potential partners available in the global arena, often 
only to be found in global biotech ‘megacentres’ (Moodysson, 2007; Moodysson and Jonsson, 
2007). For reasons like this, the initial enthusiasm over MVA as an initiative with the aim to 
strengthen local and cross-border integration has partly diminished. Several of the commercial 
actors gradually realised that ‘network promoting’ activities without substantial output in terms of 
new formal collaboration were hard to justify, and academic actors felt a growing alienation 
against what they felt was more ‘the business of the local business’ than something for them to 
engage in. As a result of this, MVA has adapted its strategy to meet the requirements of its 
members of a more dedicated focus on promoting global visibility of world class research. In its 
present ‘v e 
regional 
“initiate synergetic collaboration with other bio-regions and organizations and, together 
d members and their UK counterparts, a 
joint EU 6th Framework Program including MVA and the Scottish Enterprise, and a UK-Medicon 
Valley Post Doc Programme (MVA, 2006). The l
accor
ision and mission’ statement the focus has thus been broadened, not only to promot
integration but also:  
with others, promote and brand Medicon Valley, as well as the entire Øresund region, 
locally and globally” (MVA, 2006). 
Recent examples of this strive to link up with other global biotech ‘megacentres’ is the 
establishment of MVA ‘embassies’ in places like Kobe, Vancouver, Seoul and Beijing, as well as 
the “UK-Medicon Valley Challenge Program” initiated in 2005. The aim is to develop world class 
biotechnology research and products by promoting research exchange and interaction between 
organisations in the Medicon Valley cluster and the biotech clusters in Cambridge, London, 
Liverpool-Manchester and Edinburgh. Examples of concrete activities within the programme are 
seminars, exchange of experiences between MVA boar
ong-term vision of this collaboration is, 
ding to the MVA chairman Per Belfrage to create  
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“an air bridge from Medicon Valley to London and Cambridge, giving young scientists 
from Copenhagen and Lund the opportunity to experience these hot spots without having to 
amilies and without having to worry about exorbitant housing prices”. 
 these firms are engaged in or affected by 
research and development related to life science. When omitting those that only have sales or 
service departments in the region, or for other reasons cannot be classified as knowledge intensive 
firms, the number is reduced to approximately 150 companies. Of these 150 firms, 130 can be 
classified as DBFs while the remaining 20 are either large pharmaceuticals or medtech firms.. The 
10 largest firms in Medicon Valley are: 
c. 
move f
 
Major actors of the cluster 
a) Firms 
Firms are key actors in the cluster as main drivers for innovation and industrial dynamics. 
According to MVA there are in total 130 biotech companies, 70 pharma companies and 130 
medtech companies located in the region. not all of
 
   Empl. Loc.     Empl. Lo
1. Novo Nordisk A/S   9000 DK 6. Unomedical A/S  1200 DK 
2. H. Lundbeck A/S  2100 DK 7. AstraZeneca R/D Lund  957 SE 
3. Coloplast A/S   1990 DK 8. Pfizer Health AB  850 SE 
4. Novozymes A/S  1669 DK 9. Radiometer A/S  847 DK 
5. Leo Pharmaceutical  1270 DK 10. Chr. Hansen A/S  725 DK 
  
b) Universities 
Universities are other important actors in Medicon Valley. Their role can be described according 
to three tasks. Firstly, they provide training and education to create and sustain a skilled pool of 
local researchers and scientists. Secondly, universities conduct publicly funded scientific research 
which can serve as knowledge input for DBFs. Finally, there is the so-called ‘third task’ of 
universities which refers to direct collaboration between university and industry in the form of 
contract research as well as commercializing scientific research through licenses and start-ups of 
knowledge-intensive firms by university researchers. The most important universities in the 
region have been the universities of Lund and Copenhagen due to their long history of scientific 
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excellence in medicine, biology and chemistry. Below we provide a general overview of the most 
important universities related to Medicon Valley.    
Lund University was founded in 1666 and hosts eight faculties and a multitude of research 
centres and specialized institutes. It is today the largest unit for research and higher education in 
Sweden covering more or less all academic disciplines. The university has approximately 40 000 
stud
 – In 2005 the faculty had 2500 undergraduate students, 950 postgraduate 
students with 130 dissertations presented annually, while staff consisted of 139 professors and 450 
othe
building centres of excellence as part of a general development towards a more entrepreneurial 
ents and 6000 employees. More than 3000 post-graduates work at Lund University. Most 
doctorates are awarded in the medical sciences, followed closely by technology and the natural 
sciences. In 2006 the University had 581 professors. About half of all research at the University is 
externally financed.  
Faculty of Medicine
r teachers and researchers. The faculty collaborates intensively with the university hospitals in 
Lund and Malmö to create an environment with productive communication between basic 
research and the healthcare system. One of the results of this collaboration is the Biomedical 
Centre (BMC). 
The formation of the Biomedical Centre (BMC) in 2001, initiated by Lund University to 
promote life science in the region, was underpinned by similar rationale as the MVA. The BMC 
assembles all the university’s life science research under one roof, including the Stem Cell Centre 
and the Strategic Centre for Clinical Cancer Research (Create Health), located adjacent to Lund 
University Hospital. It is the largest single unit for teaching and research at Lund University, 
comprising half of the research at the Faculty of Medicine. It has a total of 700 scientists, 
including 50 affiliated professors, post-docs, Ph.D. students and technicians/administrative staffs 
working across 90 research groups. Major strongholds are today found in the fields of diabetes, 
immunology, neuroscience and cancer (BCG, 2002). This was primarily an attempt to rationalise 
the university research and strengthen the brand name of Lund University as centre of excellence 
in biomedical research. Hence, this initiative was mainly geared at strengthening the knowledge 
generation subsystem of the regional innovation system, while at the same time it contributed to 
promoting the integration of knowledge generation and early stages of knowledge exploitation. 
The concentration of related activities in one unit is completely in line with Lund University’s 
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university. The ‘flagship’ of BMC  is without doubt the Lund Strategic Research Center for Stem 
Cell Biology and Cell Therapy (Stem Cell Centre), established in 2003. Since the autumn 2006 
BMC also houses a Bioincubator unit, which draws both on the concept of IDEON Incubation, 
and the services of Teknopol at (the immediately adjacent) IDEON, which was the first science 
park
ersity of Copenhagen has selected 
four Research Priority Areas for the years 2003 to 2007. The Research Priority Areas are set up to 
promote cross-faculty co-operation, encourage interdisciplinary research and education and 
cation of research results and dialogue with society. One of these research 
areas is ‘Biocampus’ targeting core biotechnological research. 
c) Resea
In addition to f
and discove
Carlsberg Research Center is an independent private research centre and part of 
 to be established in the Nordic countries in 1985, and on (the university-hospital hybrid) 
BMC as a source of new businesses, to extend the scope of commercialisation undertaken by the 
university to the active formation of biotech firms. 
The University of Copenhagen was founded in 1479 and is the first university of Denmark. 
Spread over eight faculties from January 2007 after the integration of Danish University of 
Pharmaceutical Science and Royal Veterinary and Agricultural University as two new faculties, 
there are approximately 37000 students and more than 7000 employees. Except for management 
and engineering faculties, the University of Copenhagen qualifies as a broad, comprehensive 
university. Most relevant for Medicon Valley are the Faculties of Health Sciences (Medicine) and 
Science (as well as parts of the two new faculties). The Univ
strengthen the communi
 
ch institutes 
irms and universities, research institutes play an important role for basic research 
ry. The most important institutes in Medicon Valley are:  
Carlsberg A/S. Traditional competences are in malting, brewing and fermentation but it 
has become increasingly active in biotechnological production processes and biomedical 
sciences to target early drug discovery.   
The Hagedorn Research Institute is an independent basic research component within 
Novo Nordisk A/S in the field of diabetes and its complications. The three main areas of 
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research activity are (1) stem cell research & developmental biology of the pancreas (2) 
immunology and genetics of Type 1 Diabetes and (3) structural and systems biology of 
ligands and receptors of the insulin peptide family. The institute also fulfils an 
con Valley Academy (MVA). 
xpert assistance and research in different aspects of drug and 
devi
iversity Hospital.  
d) N
e knowledge 
databases and has initiated a range of working groups to analyze regional competences within 
specific subject areas. In addition, MVA contributes
educational mission by training a substantial number of masters and PhD students in 
collaboration with Danish universities, the Ministry of Science, Technology and 
Innovation (VTU) and the Medi
AstraZeneca's respiratory research unit in Lund with approximately 800 research 
employees, accounts for roughly two-thirds of inflammation and immunology R&D in 
Medicon Valley. 
Health care institutions supply e
ce development. The most important hospitals are Copenhagen Hospital Corporation, 
Copenhagen County Hospital, Lund University Hospital and Malmö Un
etwork organizations 
Network organizations have proven to be key venues and meeting grounds that provide the 
social platforms to exploit the opportunities of co-location in a cluster.  
Medicon Valley Alliance (MVA): The largest and probably most important network 
organization for Medicon Valley with 280 members (counted January 2008). If any, MVA should 
be considered as the cluster organization. As a member financed network organization it works to 
promote the necessary interaction for network formation and knowledge transfer between 
academia, public health, and biotech related industries. Important tools in this are seminars and 
conferences, as well as initiating and coordinating projects associated with educational, scientific 
and business activities in the region. MVA also sets up and manages comprehensiv
 to the regional and international marketing of 
Medicon Valley by visiting and presenting the cluster at conferences and other events and, as 
mention above, by establishing ‘embassies’ in other important bioregions globally.  
MVA is a non-profit association predominantly based on revenues generated through 
membership fees. In 2005, these constituted 75% (Denmark, 52% and Sweden 23%) of the total 
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annual turnover of approximately 1.2 million euros. 47% of the total membership fee is paid by 
private funds while 53% is funded publicly. The remaining 25% were accounted for by a 
contribution from the ØresundScience Region (13%), PhD administration (5%), sponsorships and 
funds (4%), a VINNOVA project (2
 increases quality and efficiency among the participating 
institutions by opening up all courses, libraries and other facilities to all students, teachers and 
researchers.
rsities, industry and the public 
sector. The six ØSR platforms are: Medicon Valley Academy; Øresund IT Academy; Øresund 
y; Øresund Logistics; Øresund Design. The 
activ
 close proximity may be hampered because of this. In other 
words, cross-border regional interaction is only weakly developed. In addition, extensive parts of 
the regulative environm
%), and seminar fees (1%). In total, MVA has a staff of 10 
people responsible for daily operations and a board of directors of 15 representing the different 
members of the organization. The board of directors is elected at the annual general assembly.  
Øresund University: This is a consortium of fourteen universities and university colleges in 
the Øresund region with the objective to
 Of the fourteen universities, four are Swedish and ten are Danish. The number of 
Danish and Swedish students, however, is about the same. Øresund University is, similar to 
MVA, part of Øresund Science Region. 
Øresund Science Region: ØSR joins the forces of six regional research and innovation 
platforms, Øresund University and a number of regional co-ordination bodies in an attempt to 
strengthen regional co-operation and integration between unive
Food Network; Øresund Environment Academ
ities of the platforms include establishing partnerships, benchmarking, enhancing research 
and education, innovation, technology transfer and marketing.     
Barriers to the development of the cluster 
The cluster is unique in being located in a region that spans parts of two different countries. 
This feature can and should not be ignored as a weakness of the cluster compared to similar life 
science clusters in scope and size such as nearby Stockholm-Uppsala. The national border 
contains a liability for fragmentation of cluster activities. This paper shows that the full potential 
for synergy effects derived from
ent (e.g. tax-rules, employment legislation) as well as research and 
innovation policy is shaped and implemented within a national framework which complicates 
cross-border cluster interaction. 
 11
Part of the explanation of cluster fragmentation, can be the imbalance between the different 
parts of Medicon Valley. The Danish side is strongly characterized by being the capital city region 
and the only major urban area in the country. More or less by default, there is a lot of business 
activity going on in terms of financial markets, presence of business headquarters as well as 
political activity. Scania, on the Swedish side, is typically a second tier region being relatively far 
away from the action in the capital Stockholm. In terms of inhabitants, number of firms 
(especially big pharma), venture capital investors there is clearly a skewed distribution in favor of 
the D
f technology transfer offices is still 
in the process of catching up and considerable progress is being made. A lot of policy efforts can 
supply of venture capital.     
The role o
anish part of Medicon Valley. As for university and research facilities however, the situation 
is more balanced. 
Another potential barrier to the development of the cluster is the somewhat disappointing 
results in commercializing academic research especially compared to North-American life science 
clusters. Measured in terms of establishing start-up companies or license agreements following 
patent filings, the Medicon Valley universities (and university hospitals) fall behind important 
competitors such as Karolinska Institute in Stockholm, Oxford University and Stanford University 
alone. Partly, this can be explained by the fact that ‘the entrepreneurial university’ has its origin in 
the US while Europe in general (with the exception of the UK) is following suit. Therefore, it 
should be emphasized that legislation and the establishment o
be expected to contribute in this. Another disadvantage, at least compared to the North American 
life science clusters, is the lower 
f public policy at national, regional and local levels in promoting the cluster 
overcoming barriers 
Both countries have thriving innovation policy environments. The main governmental 
innovation body in Sweden is VINNOVA (Swedish Agency for Innovation Systems) which has 
been established in 2001. It has an annual budget of about 110 million euro to support innovation 
on a national, regional and sectoral level in active collaboration with industry and academia 
(following the triple helix model). Life sciences are broadly covered in four so-called growth 
areas: ‘drugs and diagnostics’, ‘biotechnical tools’, ‘medical technology’ and ‘innovative food’. It 
can therefore be seen as a prioritized technological platform in Swedish innovation policy not the 
least because it receives approximately one tenth of the total annual budget. Moreover, 
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VINNOVA has committed itself to support the absorption of biotechnology in the food sector in 
Scania through its regional innovation systems program VINNVÄXT. In Denmark, innovation 
policy is coordinated through the Ministry of Science, Technology and Innovation (VTU). 
Compared to Sweden, there is less explicit state support and involvement for innovation or triple 
helix collaboration. VTU supports however ‘innovation consortia’ to enhance cooperation 
between public institutions and private enterprises. An example of this is the recently established 
Danish Pharma Consortium under initiative of four Danish Medicon Valley universities 
(Copenhagen University, Danish Technical University, Danish University of Pharmeceutical 
Science and the Royal Veterinary and Agricultural University). Another important component of 
Danish innovation policy are the 15 national Business Service Centres (Erhvervsservicecentre) to 
provide counseling and information to SMEs at a local level. The aforementioned incubator 
facilities should also be mentioned as part of both countries’ innovation policy. In sum, therefore, 
it needs to be emphasized that the innovation policy environment for Medicon Valley is very 
strongly divided along national boundaries. There is
mportant, and innovation policies, promoting the formation of regional 
innovation systems, primarily for supporting high-tech industries. So far, out of 8 Vinnväxt 
projects, three belong to the biotech sector (t
his is the pharmaceutical industry, which 
is research intensive and dominated by large companies. The support of this industry mainly takes 
 no systematic collaboration or coordination 
between VINNOVA and VTU for Medicon Valley.  
Even if Medicon Valley is not a direct result of national or regional political initiatives, it has 
indirectly benefited from the favourable political environment for supporting high-tech as well as 
cluster development. Sweden has for many years pursued an active innovation policy through the 
national responsible agency VINNOVA. This has been a combination of technology policies, 
supporting specific, strategic technologies and sectors – of which biotech was/is considered to be 
one of the most i
wo red bio in Gothenburg and Uppsala, and one 
green bio in Lund). 
Denmark on the other side has a tradition of less direct public intervention, and leaves more 
to the market. Thus, Denmark, which in contrast to Sweden, is dominated by SMEs, is 
characterised by a market-driven innovation system supporting non-R&D based, incremental 
consumer product innovations. One of the exceptions to t
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the form of science policies of funding basic research at universities and research institutes, even 
if it amounts to less than the similar funding in Sweden.  
As has already been stated in the paper the establishment of Medicon Valley 
Academy/Alliance is a result of an Interreg project initiated by Lund and Copenhagen 
universities. The strategic role of universities as the key providers of new knowledge is evident 
with respect to promoting the formation of biotechnology and other high-tech clusters. Lund 
University has undergone a transition from a traditional Humbolt type university to become an 
entr
other universities and research organisations in order to get bigger and stronger universities. The 
mer
ind the establishment 
and development of Medicon Valley is the efficient and well-functioning public-private 
boration between university and both big pharma and 
small DBFs, venture capital raising, and general support for cluster formation. The regional level 
offers particular favourable conditi
arious actors and agencies. 
epreneurial university taking and implementing strategic decisions (Melander, 2006). One 
example of such strategic decision making is the building of transdisciplinary and transfaculty 
research centres, such as the Biomedical and Stem cell centres mentioned earlier in the report, 
which is located in the so called tenth area directly under the vice-chancellor.  
In Sweden, as is the case also in Finland and Norway, the universities have got a so called 
‘third mission’ in addition to teaching and research, i.e. to cooperate with the surrounding society 
on everything from commercialisation of new knowledge to policy advice. Denmark on the other 
hand tries to achieve this by giving the universities an external majority in their boards, which 
elects the vice-chancellor, and by giving increased authority to appointed leaders on faculty and 
departments levels. Another part of this strategy is the initiative to force universities to merge with 
ger of Copenhagen University with Danish University of Pharmaceutical Science and Royal 
Veterinary and Agricultural University mentioned before is one such example, becoming on of 
three so called ‘super universities’ in Denmark. This merger might have some positive effects on 
strengthening basic research relevant for the biotech industry, and, thus, for Medicon Valley. 
Moreover, another important element of the bottom-up initiative beh
partnerships with respect to research colla
ons for such partnerships due to the presence of social capital 
as well as spatial and social proximity between v
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Future policy challenges
Based on the above analysis, the following strengths, weaknesses, opportunities, and threats 
for Medicon Valley are identified (see table 2). 
Table 2. SWOT analysis o
•  of big pharma 
 
•  chain 
• ing in four therapeutic 
strongholds 
• Presence o rganization 
Medicon  
• Embedded in global knowledge 
networks 
 
 
• Cluster fragmentation along national 
borders 
• Imbalance  
• Weak commercialization of academic 
research 
 
 
 
Weaknesses 
 for the cluster 
f Medicon Valley 
 
Local presence
• Large number of small and medium
sized DBF 
• Strong academic research 
Extensive breadth in value
components 
World lead
f network o
 Valley Alliance
Strengths 
 
 
 
 
 
Opportunities 
 
• Inter-sector collaboration (food) 
Threats 
 
 
• Dependence on big pharma 
 
• Increased cross-border integration 
• Quality of life 
 
 
 
In principle Medicon valley has many essential cluster components in place in terms of key 
players in the drug development value chain (big pharmaceutical companies cooperating with 
small and medium sized DBF in new drug development), support infrastructures and presence of 
skilled researchers. As such, it ranks high in the hierarchy of global bioregions. However, the 
cluster is unique in being located in a region that spans parts of two different countries. This 
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feature can and should not be ignored as a future policy challenge of the cluster compared to 
similar life science clusters in scope and size such as nearby Stockholm-Uppsala. The national 
border contains a liability for fragmentation of cluster activities. The full potential for synergy 
effects derived from close proximity may be hampered because of this. In other words, cross-
border regional interaction is only weakly developed. In addition, extensive parts of the regulative 
environm
velopment of bio-
agro research and industry connected to the VINNOVA Vinnväxt initiative ‘Food innovation at 
interfaces’, which as on
try cooperation has been by far the most important and successful, 
while the public sector’s contribution has been of minor importance, and can partly be said to be 
responsible for som
ent (e.g. tax-rules, employment legislation) as well as research and innovation policy is 
shaped and implemented within a national framework which complicates cross-border cluster 
interaction. 
Diversification opportunities lie primarily in exploiting biotechnology as a generic platform 
technology through expanding its application into new areas of related variety, e.g. green and 
white biotechnology. This diversification process has already begun with the de
e of its potential growth areas focus on ‘functional food’. Building on the 
idea of related variety will secure maximal knowledge spillover effects by combining industries 
with complementary and differentiated knowledge bases (Asheim et al., 2006).  
The SWOT analysis emphasized furthermore the competitive advantage of having a 
combination of big pharma and a stock of small and medium-sized DBFs, the presence of strong 
academic research as well as well-developed links to the leading global nodes of the industry. 
These factors point at the necessity of both building-up and strengthening the endogenous 
knowledge infrastructure (universities and research institutes) and stimulating cooperation with 
national and international leading research institutions and companies. The Nordic tradition for 
cooperation and collaboration, also found in Medicon Valley, is according to the SWOT analysis 
perhaps the most important individual factor contributing to its success. Of these collaborative 
relationships university-indus
e of the shortcomings of the cluster (e.g. the lack of harmonization in policies 
between the two parts of the cluster which, however, must be blamed on the two parts belonging 
to different national states).  
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The encouraging lesson to be learned from Medicon Valley is, however, how much that can 
be achieved and accomplished on a regional level, if the necessary and strategic resources as well 
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